NASDAQ: YDESYd Bio Ltd Stock
$3.83-0.17 (-4.25%)
Updated Sep 14, 2026
YDES Price
$3.83
Fair Value Price
-$0.10
Market Cap
$271.33M
52 Week Low
$1.70
52 Week High
$22.00
P/E
N/A
P/B
60.65x
P/S
128.5x
PEG
N/A
Dividend Yield
N/A
Revenue
$1.24M
Earnings
$305.76k
Gross Margin
29.6%
Operating Margin
24.67%
Profit Margin
24.7%
Debt to Equity
1.25
Operating Cash Flow
-$7M
Beta
0.04
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
YDES Overview
Breeze Holdings Acquisition Corp. is a "blank check" company formed to effect mergers, share exchanges, asset acquisitions, stock purchases, recapitalizations, reorganizations, or related business combinations. It targets businesses in the energy sector in North America. Breeze Holdings was incorporated in 2020 and is based in Irving, TX.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine YDES's potential to beat the market
- YDES doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
YDES
RankedUnranked of 459
RankedUnranked of 459
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $9.14 | A | |
| $6.85 | A | |
| $41.54 | A |
Be the first to know about important YDES news, forecast changes, insider trades & much more!
YDES News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how YDES scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
YDES ($3.83) is overvalued by 3,872.82% relative to our estimate of its Fair Value price of -$0.10 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
YDES ($3.83) is not significantly undervalued (3,872.82%) relative to our estimate of its Fair Value price of -$0.10 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
YDES is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
There are 30 more YDES due diligence checks available for Premium users.
Valuation
YDES fair value
Fair Value of YDES stock based on Discounted Cash Flow (DCF)
Price
$3.83
Fair Value
-$0.10
Undervalued by
3,872.82%
YDES ($3.83) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
YDES ($3.83) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
YDES price to earnings (PE)
For valuing profitable companies with steady earnings
Company
0x
Industry
8.25x
Market
43.6x
YDES price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
60.65x
Industry
5.35x
YDES is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
YDES's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
YDES's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
YDES's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$10.1M
Liabilities
$5.6M
Debt to equity
1.25
YDES's short-term assets ($5.59M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
YDES's short-term assets ($5.59M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
YDES's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
YDES's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
YDES's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
YDES vs Biotech Stocks
Yd Bio Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.